Will AstraZeneca plc, Shanks Group plc And Sports Direct International Plc Make Storming Comebacks?

Are these 3 stocks worthy of ‘turnaround’ status? AstraZeneca plc (LON: AZN), Shanks Group plc (LON: SKS) and Sports Direct International Plc (LON: SPD).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in waste disposal company Shanks (LSE: SKS) have fallen by 4% today after it released a profit warning. Its update stated that market conditions in the oil, gas and electricity sectors have been challenging and this means that it now expects to miss forecasts for the full year. It also separately announced the sale of a non-core asset for £30m.

Despite the difficult trading conditions, Shanks’ commercial division has continued to deliver strong profit growth, driven by the company’s self-help initiatives. And its hazardous waste division has also traded robustly despite the deterioration in the oil and gas sector, which makes up around half of its sales. But with Shanks’ municipal division delivering worse performance than expected, its near-term outlook remains very challenging.

Looking ahead, Shanks was expected to post a fall in earnings of 5% prior to today’s update. As such, investor sentiment could worsen in the near term as the market begins to price-in an additional deterioration in its profit outlook. And even though Shanks is expected to rebound with double-digit earnings growth next year, its price-to-earnings (P/E) ratio of 17.7 indicates that its risk/reward ratio is relatively unfavourable at the present time.

Turnaround stock?

Also recording a falling share price today is Sports Direct (LSE: SPD), with its shares having declined by almost 30% since the turn of the year due in part to its own profit warning. This was at least partly because of challenging performance in its European division and while disappointing, international expansion could still offer improved growth prospects for the company in the long run.

Clearly, Sports Direct is often in the news regarding its staffing policies, but it remains one of the most successful British retailers of recent years. Its business model was able to adapt to the cost of living crisis during the Credit Crunch and now needs to adapt to a UK consumer who has higher disposable income in real terms.

This could be a challenge and the company’s share price may come under pressure in the short run as its dirt cheap pricing could hold less appeal with wage growth being higher than inflation. But Sports Direct’s price-to-earnings growth (PEG) ratio of 1 indicates that it could become a top notch turnaround stock.

Better times ahead?

Similarly, AstraZeneca (LSE: AZN) is also enduring a very challenging period at the present time, with the pharmaceutical company being forced to come to terms with a patent cliff that has caused a severe decline in its earnings in recent years. Looking ahead, this is set to continue, with AstraZeneca expected to report a fall in its bottom line of 6% in the current year.

However, while this is disappointing, the market appears to be looking further out to AstraZeneca’s expected turnaround. With its pipeline gaining momentum through multiple acquisitions and drug development/approval news being relatively encouraging (as recent news has shown), investor sentiment could improve and push the company’s share price higher after its decline of 4% in the last year. And with AstraZeneca trading on a P/E ratio of 15.9, it continues to offer excellent turnaround potential.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca and Sports Direct International. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

£5,000 of 9.2%-yielding Legal & General shares could make me £599 a month in passive income over time!

Legal and General shares remain a top passive income stock in my core portfolio holdings, with a 9.2% yield and…

Read more »

Investing Articles

With a 10.4% yield, P/E ratio of 9.9, and a P/B of 0.37, is this FTSE 100 stock a no-brainer buy for me?

Using a range of popular valuation measures, this FTSE 100 stock appears to offer tremendous value for money. So is…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Down nearly 18% from its 52-week high, is the Lloyds share price now a screaming buy for me?

In recent weeks, the Lloyds share price has under-performed the wider market. Could this be the buying opportunity that I’m…

Read more »

Investing Articles

As BAE Systems’ share price drops 14% should I buy more?

FTSE 100 defence giant BAE Systems recently reiterated strong growth guidance, leaving its share price looking significantly undervalued to me.

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

After an 18% jump on its 2024 results, is it too late for me to consider buying this FTSE 100 hidden gem?

This FTSE 100 technology firm unveiled very strong 2024 results recently and a big share buyback, but is it too…

Read more »

Investing Articles

£5,000 invested in Rolls-Royce shares in 2023 would have made this much by now

Rolls-Royce shares have been one of the best-performing UK FTSE 100 investments over the last two years. But how much…

Read more »

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

£5,000 invested in Lloyds shares in 2023 would be worth this much now

Lloyds shares and other banking stocks have thrived in 2024, but has it been a good investment for shareholders who…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

Why are investors blowing a raspberry at this FTSE 250 stock?

After a successful IPO, the share price of this FTSE 250 stock's fallen. Our writer looks at the reasons and…

Read more »